Bayer Nubeqa Gets NMPA Approval for Metastatic Prostate Cancer
Bayer AG (ETR: BAYN) announced that the National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide)...
Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data
Daiichi Sankyo (TYO: 4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting...
Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone
Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study...
PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform
PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immuno‑inflammation biotech founded in 2016, made an initial public...
Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the U.S. Food and Drug Administration...
Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis
Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive...
ZEISS ARTEVO Gets NMPA Approval for China Ophthalmology Market
ZEISS Medical Technology announced that the National Medical Products Administration (NMPA) has approved the ARTEVO...
Venglustat Gaucher: Sanofi Meets Primary Endpoint in Phase 3 LEAP2MONO Study
Sanofi (NASDAQ: SNY) announced positive results from the LEAP2MONO phase 3 study (NCT05222906), showing venglustat met the...
Arctic Vision-Mdco Technology Merger Builds Ophthalmology Platform
Arctic Vision, a China‑based ophthalmology specialist, and Mdco Technology Co., Ltd. have agreed to integrate...
Eli Lilly to Invest $3.5B in Pennsylvania Plant for Retatrutide Production
Eli Lilly (NYSE: LLY) announced plans to invest more than USD 3.5 billion in a new manufacturing facility...
Eli Lilly Mounjaro Fails to Win EU Approval for HFpEF Heart Failure Indication
Eli Lilly (NYSE: LLY) announced that the European Medicines Agency (EMA) drug advisory panel declined to...
Imfinzi Gastric Cancer: AstraZeneca Secures CHMP Recommendation
AstraZeneca (AZ, NASDAQ: AZN) announced that the Committee for Medicinal Products for Human Use (CHMP) has...
Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China
Chiesi Group’s China unit announced that the National Medical Products Administration (NMPA) has granted marketing...
SanegeneBio Partners with Genentech on RNAi Therapy in $1.7B Deal
SanegeneBio, a Suzhou‑based RNA interference (RNAi) therapeutics developer, announced a global partnership with Genentech, a...
Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership
Zonsen Peplib Biotech Inc., a China‑based polypeptide lead compound developer, announced a collaboration with Eli...
Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis
Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for...
WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases
WuXi Biologics (HKG: 2269) announced a partnership with Vertex Pharmaceuticals for an innovative trispecific T‑cell engager...
NMPA Releases 101st Batch of Generic Reference Drugs
The National Medical Products Administration (NMPA) released the 101st batch of reference drugs for generic...
Zenshine Pharma Files for Hong Kong IPO with $357M Valuation
Nanjing Zenshine Pharmaceuticals Co., Ltd. submitted its initial public offering (IPO) filing to the Main...
Moderna Partners with Recordati on mRNA-3927 for Rare Propionic Acidemia
Moderna Inc. (NASDAQ: MRNA) announced a global partnership with Italy‑based Recordati for mRNA-3927, an investigational mRNA...